Tufts University

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Regeneron Bolsters Ophthalmic Portfoli

Cardurion Pharmaceuticals Inc. raised $260m in series B venture capital to fund ongoing Phase II clinical trials in heart failure and a rare genetic arrhythmic disease for its two lead drug candidate

The biopharmaceutical industry is nearing the one-month mark without an initial public offering in the US as biotechnology stock values continue to plummet, mirroring the slowdown across industries as

Vor Hopes NCI’s CAR-T Candidate Is Synergistic With Lead AML Therapy PureTech Health plc -backed Vor Biopharma Inc. said on 11 November that it has licensed a clinical-stage chimeric antigen recept